Antibody-drug conjugate (ADC) cancer therapeutics developer
| Date | Round | Amount |
|---|---|---|
| Jun 2022 | Seed Spirea, a Cambridge antibody-drug-conjugate biotech, raised £2.4M from UK and US investors. | $2.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.